Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Knobler Robert; Geroldinger-Simic Marija; Kreuter Alexander; Hunzelmann Nicolas; Moinzadeh Pia; Rongioletti Franco; Denton Christopher; Mouthon Luc; Cutolo Maurizio; Smith Vanessa; Gabrielli Armando; Bagot Martine; Olesen Anne B.; Foeldvari Ivan; Jalili Ahmad; Kähäri Veli Matti; Karpati Sarolta; Kofoed Kristian; Olszewska Malgorzata; Panelius Jaana; Quaglino Pietro; Seneschal Julien; Sticherling Michael; Sunderkotter Cord; Tanew Adrian; Wolf Peter; Worm Margitta; Skrok Anna; Rudnicka Lidia; Krieg Thomas
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxoedema and scleroedema

Knobler Robert
Geroldinger-Simic Marija
Kreuter Alexander
Hunzelmann Nicolas
Moinzadeh Pia
Rongioletti Franco
Denton Christopher
Mouthon Luc
Cutolo Maurizio
Smith Vanessa
Gabrielli Armando
Bagot Martine
Olesen Anne B.
Foeldvari Ivan
Jalili Ahmad
Kähäri Veli Matti
Karpati Sarolta
Kofoed Kristian
Olszewska Malgorzata
Panelius Jaana
Quaglino Pietro
Seneschal Julien
Sticherling Michael
Sunderkotter Cord
Tanew Adrian
Wolf Peter
Worm Margitta
Skrok Anna
Rudnicka Lidia
Krieg Thomas
Katso/Avaa
Lataukset: 

Wiley-Blackwell
doi:10.1111/jdv.19937
URI
https://doi.org/10.1111/jdv.19937
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2025082791818
Tiivistelmä

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present consensus provides an update to the 2017 European Dermatology Forum Guidelines, focusing on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, updated strategies for the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this consensus provides clinicians with an overview of the diagnosis and treatment of scleromyxoedema and scleroedema (of Buschke).

Kokoelmat